全文获取类型
收费全文 | 5493篇 |
免费 | 286篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 83篇 |
儿科学 | 94篇 |
妇产科学 | 56篇 |
基础医学 | 721篇 |
口腔科学 | 80篇 |
临床医学 | 629篇 |
内科学 | 1323篇 |
皮肤病学 | 242篇 |
神经病学 | 614篇 |
特种医学 | 229篇 |
外科学 | 513篇 |
综合类 | 20篇 |
一般理论 | 3篇 |
预防医学 | 259篇 |
眼科学 | 173篇 |
药学 | 501篇 |
中国医学 | 6篇 |
肿瘤学 | 262篇 |
出版年
2023年 | 16篇 |
2022年 | 32篇 |
2021年 | 64篇 |
2020年 | 49篇 |
2019年 | 62篇 |
2018年 | 71篇 |
2017年 | 76篇 |
2016年 | 94篇 |
2015年 | 105篇 |
2014年 | 162篇 |
2013年 | 209篇 |
2012年 | 325篇 |
2011年 | 328篇 |
2010年 | 250篇 |
2009年 | 217篇 |
2008年 | 345篇 |
2007年 | 371篇 |
2006年 | 381篇 |
2005年 | 320篇 |
2004年 | 345篇 |
2003年 | 314篇 |
2002年 | 336篇 |
2001年 | 111篇 |
2000年 | 76篇 |
1999年 | 122篇 |
1998年 | 85篇 |
1997年 | 71篇 |
1996年 | 59篇 |
1995年 | 52篇 |
1994年 | 43篇 |
1993年 | 28篇 |
1992年 | 36篇 |
1991年 | 37篇 |
1990年 | 31篇 |
1989年 | 25篇 |
1988年 | 36篇 |
1987年 | 27篇 |
1986年 | 18篇 |
1985年 | 30篇 |
1984年 | 32篇 |
1983年 | 19篇 |
1982年 | 22篇 |
1981年 | 19篇 |
1980年 | 31篇 |
1979年 | 19篇 |
1978年 | 18篇 |
1977年 | 16篇 |
1976年 | 16篇 |
1975年 | 17篇 |
1962年 | 12篇 |
排序方式: 共有5808条查询结果,搜索用时 31 毫秒
1.
2.
3.
Background
In order to reduce systematic errors (such as language bias) and increase the precision of the summary treatment effect estimate, a comprehensive identification of randomised controlled trials (RCT), irrespective of publication language, is crucial in systematic reviews and meta-analyses. We identified trials in the German general health care literature. 相似文献4.
Parastoo Jangouk Thomas Dehmel Gerd Meyer Zu Hörste Andreas Ludwig Helmar C. Lehmann Bernd C. Kieseier 《Glia》2009,57(16):1765-1774
The disintegrin and metalloproteinase 10 (ADAM10) is a membrane‐anchored metalloproteinase with both proteolytic and disintegrin characteristics. Here, we investigate the expression, regulation, and functional role of ADAM10 in axonal outgrowth and myelination of the peripheral nerve. Expression pattern analysis of 11 ADAM family members in co‐cultures of rat dorsal root ganglia (DRG) neurons and Schwann cells (SCs) demonstrated the most pronounced mRNA expression for ADAM10. In further studies, ADAM10 was found to be consistently upregulated in DRG‐SC co‐cultures before the induction of myelination. Neurons as well as SCs widely expressed ADAM10 at the protein level. In neurons, the expression of ADAM10 was exclusively limited to the axons before the induction of myelination. Inhibition of ADAM10 activity by the hydroxamate‐based inhibitors GI254023X and GW280264X resulted in a significant decrease in the mean axonal length. These data suggest that ADAM10 represents a prerequisite for myelination, although its activity is not required during the process of myelination itself as demonstrated by expression analysis of myelin protein zero (P0) and Sudan black staining. Hence, during the process of myelin formation, ADAM10 is highly upregulated and appears to be critically involved in axonal outgrowth that is a requirement for myelination in the peripheral nerve. © 2009 Wiley‐Liss, Inc. 相似文献
5.
Prof. Dr. Wolfgang Dörr Sabine Köst Klaus Keinert Felix-Herbert Glaser Gerd Endert Thomas Herrmann 《Strahlentherapie und Onkologie》2006,182(1):1-8
PURPOSE: To compare tests for intestinal function with clinical scores after abdominal irradiation. PATIENTS AND METHODS: At the Department of Radiotherapy, Erfurt, Germany, intestinal changes were studied in 91 patients receiving abdominal radiotherapy between 1992 and 1996. Conventional fractionation (1.8-2 Gy per fraction, total doses 30.6-62.5 Gy) was applied. Before and at weekly intervals during radiotherapy, the clinical response was scored according to RTOG/EORTC for the upper and lower gastrointestinal (GI) tract. Resorption tests for vitamin B(12) and D-xylose were performed before the onset and immediately after treatment. RESULTS: The clinical response displayed a well-defined dose-effect relationship with grade 1 effects in 5% and 50% of the patients at about 10 Gy and 50 Gy, respectively. For grade 2 reactions, 5%- and 50%-effective doses were 20-30 Gy and 60-80 Gy. Effects in the upper and lower GI tract were highly correlated. Changes in body weight did not show a correlation with other clinical symptoms. Changes in resorption also displayed a significant dose effect. However, no correlation was found with the clinical symptoms in the individual patient. CONCLUSION: In the present study, the clinical manifestation of intestinal side effects according to RTOG/EORTC criteria was reflected by neither the vitamin B(12) nor by the D-xylose resorption test. Hence, these tests cannot be regarded as useful for objective quantitation of intestinal radiation injury. 相似文献
6.
Bergner Raoul; Hoffmann Martin; Riedel Klaus-Dieter; Mikus Gerd; Henrich Dirk M.; Haefeli Walter E.; Uppenkamp Michael; Walter-Sack Ingeborg 《Nephrology, dialysis, transplantation》2006,21(4):1019-1023
To cover intermediate sensitive Candida glabrata in ICU patients,fluconazole plasma peak levels at least in the range of 1632µg/ml appear necessary for treatment. Previous studiesdid not reach these fluconazole levels under continuous veno-venoushaemofiltration (CVVHF) with dosages of 200600 mg fluconzoledaily. In the present study, nine patients simultaneously requiringCVVHF for treatment of acute oligoanuric renal failure and antimycotictherapy of Candida septicemia received fluconazole 800 mg/day.Fluconazole plasma levels were determined to evaluate whetherthis dosage is adequate to reach the advised fluconazole levels.Patients were dialysed on two consecutive days with an ultrafiltrationrate (UF) of 1000 ml/h or 2000 ml/h, respectively, in a randomizedorder. The predilution was 800 ml/h and 1800 ml/h, respectively.The treatment was tolerated without adverse effects. All patientsreached plasma fluconazole concentrations between 16 and 32µg/ml, remaining in this range for a minimum of 1 up to24 h with a mean of 9.6 h and a UF rate of 2000 ml/h, and 15.7h with a UF rate of 1000 ml/h. So far, there are no in vivodata on the fluconazole plasma concentrations required for effectivetreatment. However, our data demonstrate, that at least thefluconazole concentrations desirable on the basis of in vitrosusceptibility testing can be reached in critically ill patientson CVVHF in an ICU setting. However, in these patients, 800mg fluconazole/day are necessary to achieve fungicidal drugconcentrations. 相似文献
7.
8.
Tobias Engelhorn Sophia Goerike Arnd Doerfler Christine Okorn Michael Forsting Gerd Heusch Rainer Schulz 《Journal of cerebral blood flow and metabolism》2004,24(4):467-474
The goal of the present study was to test the impact of administration time of the angiotensin II type 1-receptor blocker candesartan on cerebral blood flow (CBF), infarct size, and neuroscore in transient cerebral ischemia. Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion. Rats received 0.5-mg/kg candesartan intravenously 2 hours before MCAO (pretreatment), 24 hours after MCAO, every 24 hours after MCAO, or 2 hours before and every 24 hours after MCAO. Infarct size (mm3) and a neuroscore at day 7 were compared with controls. CBF was quantified by radiolabeled microspheres and laser-Doppler flowmetry. Compared with controls (95 +/- 8), infarct size in candesartan-treated groups was smaller (59 +/- 5, 68 +/- 10, 28 +/- 3, and 15 +/- 3, respectively; P<0.05). Although there was no difference in neuroscore between pretreatment and controls (1.55 +/- 0.18, 1.80 +/- 0.13), other treatment regimens resulted in improved neuroscores (1.33 +/- 0.16, 1.11 +/- 0.11, 0.73 +/- 0.15; P<0.05). CBF in pretreated animals at 0.5 hours after MCAO was significantly higher than in controls (0.58 +/- 0.09 mL x g(-1) x min(-1) and 44% +/- 7% of baseline compared with 0.49 +/- 0.06 mL x g(-1) x min(-1) and 37% +/- 6%, microspheres and laser-Doppler flowmetry; P<0.05). Thus, candesartan reduces infarct size even if administered only during reperfusion. Apart from pretreatment, other treatment regimens result in significantly improved neuroscores. In the acute phase of cerebral ischemia, candesartan increases CBF. 相似文献
9.
L. P. W. J. v. d. Heuvel C. H. Schröder C. O. S. Savage D. Menzel K. J. M. Assmann L. A. H. Monnens J. H. Veerkamp 《Pediatric nephrology (Berlin, Germany)》1989,3(4):406-413
Two children with Alport's syndrome are described, who developed anti-glomerular basement membrane (GBM) antibody-mediated nephritis after renal transplantation. The reactivity of antibodies in their serum with collagenase-solubilized normal GBM was examined by SDS-PAGE with one- and two-dimensional immunoblotting. The specificity was compared with that of antibodies present in serum from a patient with Goodpasture's syndrome, and a mouse monoclonal antibody (MCA-P1), directed against the Goodpasture antigen. All reacted in a similar way with collagenase-solubilized GBM. Since abnormalities in the composition of the GBM are present in Alport's syndrome, it is proposed that differing antigen composition of GBM in the host compared with the donor kidney, together with transplant rejection, may have provoked the development of post-transplant anti-GBM antibodies. 相似文献
10.